Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain wave test may reveal if your antidepressant is working

NCT ID NCT00792168

Knowledge-focused Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether brain wave patterns (measured by QEEG) can predict how well people with major depression respond to the antidepressant venlafaxine (Effexor). Thirty-eight adults with depression received either venlafaxine or a placebo for a short time, then continued with open-label treatment. Researchers monitored brain activity and depression symptoms to see if early brain changes could forecast later improvement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
venlafaxine (Effexor)
What this could lead to
If successful, this could help doctors use brain wave patterns to quickly tell if an antidepressant is working, potentially speeding up treatment decisions for depression.
What could go wrong
This is a small, early-phase study with only 38 participants, so results may not apply to everyone. The brain wave test (QEEG) is still experimental and not a proven tool for guiding treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

38 people

The number who actually took part.

Started

Nov 1996

Finished

Dec 1998

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All subjects will meet DSM-IV criteria for depression on the basis of a SCID-P interview, with subjects in the placebo controlled phase of the study having a score on the 17-item Ham-D \> 18 (with item #1 \> 2). Subjects will meet criteria both at recruitment, and after a one-week single blind placebo wash-in. - Study includes outpatients only. Exclusion Criteria: * All subjects will have no serious medical illness. * The investigators will exclude patients also meeting criteria for the following groups of axis I diagnoses: * delirium or dementia * substance-related disorders * schizophrenia or other psychotic disorders * eating disorders. * In addition, patients meeting criteria for cluster A or B axis II diagnoses will be excluded. * Subjects with a history of current or past active suicidal ideation, or suicide attempts will be excluded from the placebo-controlled phase of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depression

Contacts and locations

Locations

  • University of California

    Los Angeles, California, 90024, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.